E7389-LF

DRUG2 trials

Sponsors

Eisai Co., Ltd.

Conditions

Solid NeoplasmsSolid Tumor

Phase 1

Study of E7389 Liposomal Formulation in Participants With Solid Tumor

Active, not recruitingNCT03207672

Eisai Co., Ltd.Solid Tumor

Start: 2017-08-18End: 2027-03-31Target: 140Updated: 2026-08-27

A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor

Active, not recruitingNCT04078295

Eisai Co., Ltd.Solid Neoplasms

Start: 2019-09-05End: 2027-03-31Updated: 2026-02-10

Related Papers

E7389-LF as a first-line chemotherapy for patients with metastatic/advanced HER2-negative breast cancer: results from the phase 1 dose-expansion part of study 114

Breast Cancer Research2026-09-17

Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort.

2024-09-04

Abstract 5260: Combination activity of eribulin liposomal formulation and anti-PD-1 antibody after tumor regrowth during anti-PD-1 antibody treatment in mice

Cancer Research2024-03-22

Phase 2 small cell lung cancer (SCLC) cohort of a phase 1b/2 trial of a liposomal formulation of eribulin in combination with nivolumab.

Journal of Clinical Oncology2023-06-01

Abstract 5075: Antitumor activity of liposomal formulation of eribulin combined with anti-human PD-1 antibody using hPBMC-humanized mouse models

Cancer Research2023-04-04

The esophageal cancer cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) + nivolumab.

Journal of Clinical Oncology2023-01-24

Gastric cancer (GC) cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) in combination with nivolumab.

Journal of Clinical Oncology2023-01-24

Abstract 5584: Antitumor activity of liposomal formulation of eribulin combined with anti-PD-1

Cancer Research2022-06-151 citations

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort

European Journal of Cancer2022-04-2912 citations

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort.

Journal of Clinical Oncology2021-05-201 citations

Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study.

2021-05-1813 citations